Literature DB >> 3567055

Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time.

L A Christensen, O Slot, G Sanchez, J Boserup, S N Rasmussen, S Bondesen, S H Hansen, E F Hvidberg.   

Abstract

The influence of intestinal transit time on the release of 5-aminosalicylic acid (5-ASA) from a peroral, slow-release preparation (Pentasa) was studied at steady state in seven healthy volunteers. Daily dose was 1500 mg Pentasa, normal transit time (NTT) was 24 h (16-26 h) and accelerated transit time (ATT), caused by a laxative, was 5 h (4-9 h). Median total recovery (24 h, 5-ASA + acetyl-5-ASA) was 87% (61-129%) (NTT) and 81% (56-100%) (ATT), respectively, (P greater than 0.10). The total faecal excretion of 5-ASA (per cent of dose) increased from 16%, (9-21%) (NTT) to 29%, (16-38%) (ATT) (P less than 0.02). Free 5-ASA rose from 12% (4-19%) to 17% (10-25%), the retained part (in granules) from 4% (2-5%) to 12% (4-24%). Urinary excretion decreased correspondingly from 32% (19-59%) to 21% (11-38%), predominantly as Ac-5-ASA (P less than 0.05). Mean plasma Ac-5-ASA concentration decreased from 1.42 micrograms ml-1 to 0.86 microgram ml-1 (P less than 0.05). An almost complete release of 5-ASA from Pentasa takes place during NTT. At ATT conditions about 88% is released, indicating Pentasa to be an acceptable source of 5-ASA in diarrhoeal states.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3567055      PMCID: PMC1386240          DOI: 10.1111/j.1365-2125.1987.tb03061.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.

Authors:  J E LENNARD-JONES; J J MISIEWICZ; A M CONNELL; J H BARON; F A JONES
Journal:  Lancet       Date:  1965-01-23       Impact factor: 79.321

2.  IN VIVO DIALYSIS OF FAECES AS A METHOD OF STOOL ANALYSIS. I. TECHNIQUE AND RESULTS IN NORMAL SUBJECTS.

Authors:  O WRONG; A METCALFE-GIBSON; R B MORRISON; S T NG; A V HOWARD
Journal:  Clin Sci       Date:  1965-04       Impact factor: 6.124

3.  Assay of 5-aminosalicylate and its acetylated metabolite in biological fluids by high-performance liquid chromatography on dynamically modified silica.

Authors:  S H Hansen
Journal:  J Chromatogr       Date:  1981-12-11

4.  Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).

Authors:  P A van Hees; J H Tuinte; J M van Rossum; J H van Tongeren
Journal:  Gut       Date:  1979-04       Impact factor: 23.059

5.  5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.

Authors:  S N Rasmussen; S Bondesen; E F Hvidberg; S H Hansen; V Binder; S Halskov; H Flachs
Journal:  Gastroenterology       Date:  1982-11       Impact factor: 22.682

6.  Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.

Authors:  K Lauritsen; J Hansen; M Ryde; J Rask-Madsen
Journal:  Gastroenterology       Date:  1984-06       Impact factor: 22.682

7.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

Authors:  A S Dissanayake; S C Truelove
Journal:  Gut       Date:  1973-12       Impact factor: 23.059

8.  Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

Authors:  A K Azad Khan; D T Howes; J Piris; S C Truelove
Journal:  Gut       Date:  1980-03       Impact factor: 23.059

9.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

10.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

View more
  13 in total

Review 1.  Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.

Authors:  P S Banerjee; J R Robinson
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.

Authors:  S G Nugent; D Kumar; D S Rampton; D F Evans
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 4.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 5.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

Review 6.  Clinical pharmacokinetics of slow release mesalazine.

Authors:  M De Vos
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

Review 7.  Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

Authors:  A A van Bodegraven; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

8.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.

Authors:  L Staerk Laursen; M Stokholm; K Bukhave; J Rask-Madsen; K Lauritsen
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

9.  Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children.

Authors:  L A Christensen; J Fallingborg; B A Jacobsen; K Abildgaard; H H Rasmussen; S N Rasmussen; S H Hansen
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

Review 10.  Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.